GeneDx price target lowered to $100 from $115 at BTIG

BTIG analyst Mark Massaro lowered the firm’s price target on GeneDx (WGS) to $100 from $115 but keeps a Buy rating on the shares. The stock declined by a staggering 43% following the company’s Q1 results, which is a major overreaction that was mainly driven by mother nature and overly bullish buyside expectations, the analyst tells investors in a research note. With the major stock pullback, shares of GeneDx trade at 4 times the firm’s 2026 rev estimates, which marks an attractive entry point for investors, BTIG adds.